EP1234034A1 - Composes de transfert, leur preparation et leur utilisation - Google Patents

Composes de transfert, leur preparation et leur utilisation

Info

Publication number
EP1234034A1
EP1234034A1 EP00985060A EP00985060A EP1234034A1 EP 1234034 A1 EP1234034 A1 EP 1234034A1 EP 00985060 A EP00985060 A EP 00985060A EP 00985060 A EP00985060 A EP 00985060A EP 1234034 A1 EP1234034 A1 EP 1234034A1
Authority
EP
European Patent Office
Prior art keywords
transfer
protein
cells
cell
transfer protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00985060A
Other languages
German (de)
English (en)
Inventor
Johannes Gerdes
Thomas Scholzen
Claudia Wohlenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faustus Forschungs Cie Translational Cancer Research GmbH
Original Assignee
Faustus Forschungs Cie Translational Cancer Research GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faustus Forschungs Cie Translational Cancer Research GmbH filed Critical Faustus Forschungs Cie Translational Cancer Research GmbH
Publication of EP1234034A1 publication Critical patent/EP1234034A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to compounds which are capable of bringing associated compounds into a cell.
  • the present invention relates to a transfer compound comprising the carboxy terminal fragment of the Ki-67 protein.
  • this application comprises vectors which contain the sequence coding for the transfer compound, transfer compounds and pharmaceutical compositions comprising these transfer compounds and / or vectors. Processes for their production and the use of these transfer compounds are also claimed. Corresponding methods for the treatment or prevention of diseases by gene therapy with the aid of these transfer compounds are within the scope of the invention.
  • Protein targeting is a fundamental biological process that is controlled by highly coordinated mechanisms.
  • protein export or protein secretion takes place on specific reaction paths, for which characterized signal sequences are used to direct the proteins into the subcellular compartments involved, such as the endoplasmic reticulum, Golgi complex and vesicles.
  • Signal sequences are also used for intracellular transfer.
  • nuclear localization sequences are described for the transfer of proteins into the cell nucleus, which direct large proteins that cannot get into the nucleus through diffusion through the nuclear pores into the cell nucleus.
  • the uptake of proteins into a cell is also complexly regulated.
  • only the receptor-mediated endocytosis should be mentioned here, which serves to import specific proteins by binding to receptors on the cell membrane and then enclosing them in vesicles.
  • This process serves on the one hand to supply cells with metabolites necessary for metabolism, and on the other hand to break down proteins.
  • Receptor-mediated endocytosis also mediates cellular responses to many mediators such as peptide hormones or growth factors. After all, this process is used by viruses and toxins to get into cells.
  • substances preferably proteins, nucleic acids, non-peptide molecules such as oligosaccharides, lipids or drugs or marker molecules, into cells. Since many of the substances mentioned cannot pass through the cell membrane, various methods are used for the introduction or intracellular production of these substances.
  • viral protein as a fusion protein introduces various polypeptides into target line populations can (WO 97/05265).
  • viral proteins can trigger pleiotropic effects, preferably in mammalian cells, cell assemblies or the whole organism.
  • the EIA protein of the adenoviruses and the T antigen of Simian Virus 40 (SV40) trigger a multitude of processes in the cells. These include, for example, the initiation of DNA synthesis and the activation of various enzymes, such as dihydrofolate reductase, thymidine kinase and DNA polymerase (Nevins, JR Adenovirus E1A: Transcription regulation and alteration of cell growth control, in Doerfler, W and Böhm, P., The molecular repertoire of Adenovirus III: Biology and pathogenesis, Springer Verlag Berlin, Heidelberg, New York, 1995).
  • various enzymes such as dihydrofolate reductase, thymidine kinase and DNA polymerase (Nevins, JR Adenovirus E1A: Transcription regulation and alteration of cell growth control, in Doerfler, W and Böhm, P., The molecular repertoire of Adenovirus III: Biology and
  • the present invention is therefore based on the object of providing a transfer vehicle for connections in order to overcome these disadvantages.
  • the transfer compounds can be used in gene therapy.
  • the transfer vehicle according to the invention is from a mammal, preferably of human origin.
  • the present object is achieved according to the invention by a carboxy-terminal fragment of the human Ki-67 protein.
  • Another aspect of the present invention relates to a vector which codes for this fragment. Furthermore, a transfer protein is described which has the carboxy-terminal fragment of the Ki-67 protein.
  • the transfer protein according to the invention can be the carboxy-terminal fragment of the Ki-67 protein of humans, mice, rats or other species.
  • the invention relates to methods for producing transfer connections and for producing vectors which code for these transfer connections.
  • Another aspect is a method for transferring compounds into a target group, selected from cell lines, cells in vitro, tumor cells, tissue, etc., with the aid of the above-mentioned transfer protein according to the invention or a vector which contains the sequence coding for a transfer protein according to the invention.
  • the present invention includes the use of the above.
  • Compounds for the transfer of associated compounds as well as methods for the therapy and prevention of diseases, in particular the use in gene therapy.
  • a pharmaceutical composition containing the transfer protein according to the invention alone or in association with another compound is also provided, as well as a method for its production.
  • Figure 1 Representation of the nucleotide sequence of the Kon21 DNA insert. The numbering of the base pairs and the restriction sites used for cloning are indicated above the nucleotide sequence. The amino acid sequence of the derived Kon21 protein is shown below the nucleotide sequence.
  • Bold Nucleotides are part of the restriction sites used. Underlined nucleotides have been introduced into the construct by the deoxyoligonucleotide primers used. For a better overview, only one of the two DNA strands was given in the 5 '-3' direction.
  • FIG. 1 Microscopic images of cells 6 hours (a-d), 10 hours (e-h) and 24 hours (i-1) after
  • FIG 4 Microscopic images of cells 5 minutes (a-d) and 1 hour (e-h) after the addition of the high salt lysate, see Example 2.
  • the cells in the left half of the image were stained with MIB-21 (a, c, e, g).
  • the right half of the picture shows the same cells stained with propidium iodide (b, d, f, h).
  • the upper half of the picture shows cells after 5 minutes (a-d)
  • the lower half of the picture shows cells after 1 hour of incubation with the high salt lysate (e-h).
  • the fragment according to the invention namely the carboxy-terminal region of the Ki-67 protein, encompasses the region of amino acids from 3037 to 3256 of the Ki-67 protein, as deposited in Swiss Prot under Accession No. P46013, or fragments of the region as described by the natural variation of the genome are present.
  • the fragment can also only parts of the above Include fragments or homologs thereof as long as the function as transfer protein is retained.
  • Homolog here means that there is at least 80% homology in the amino acid residues which are essential for the function of the carboxy-terminal region as a transfer compound.
  • the human Ki-67 protein is expressed in all nuclei of proliferating cells in all active phases of the cell cycle, ie in Gl, S, G2 and mitosis, but not in resting phase GO cells (Gerdes et al. Cell cycle analysis of a cell proliferation -associated human nuclear antigen defined by the monoclonal antibody Ki -67 J. Immuno 1.13: 1710-15, 1984).
  • the cDNA of the human Ki-67 and the murine equivalent are known and do not show any significant homologies with other proteins (Schlüter et al.
  • the cell proliferation-associated antigen of antibody Ki -67 a very large, ubiqui tous nuclear protein wi th numerous repeated elements, representing a new kind of cell cycle -maintaining proteins J.
  • the murine Ki -67 cell proliferation antigen accumulates in the nucleolar and heterochro atic regions of interphase cells ant at the periphery of the mi totic chromosomes in a process essential for cell cycle progression J. Cell Sei. 109: 143-153, 1996).
  • the human Ki-67 protein has several NLS and is physiologically only detectable in the cell nucleus, except in mitosis. Only after the microinjection of antibodies could it be shown that the Ki-67 protein is formed in the cytoplasm and is transferred very quickly, presumably in supramolecular complexes, to the cell nucleus (Heyden et al.
  • KON-21 A carboxy-terminal fragment of the human Ki-67 protein, called KON-21 ( Figure 1), transiently expressed in CHO-Kl (Chinese Hamster Ovarian-Kl, ATTC No. CRL 9618) cell line cells showed a completely unexpected immunocytological distribution pattern of the produced polypeptide.
  • the KON-21 was strongly cytoplasmic in 5-20% of the cells, as with control proteins.
  • the KON-21 was also detectable in 100% of the cell nuclei. It could be shown that the Kon-21 peptide is first produced in 5-20% of the cells in the cytoplasm and, because it contains an NLS, is quickly transferred into the cell nucleus of these producer cells (Example 1 and Figure 3).
  • the KON-21 is passed on to neighboring, non-transfected cells and localized in these recipient cells in the cell nucleus.
  • This intercellular transfer of the KON-21 probably does not follow any of the conventional protein export or protein import routes described above, since the KON-21 lacks classic signal sequences for these processes.
  • the intracellular transfer into the cell nuclei is presumably via the Ran-GTP-Importin-alpha system (Goerlich D. Transport into and out of the cell nucleus EMBO J. Vol. 17: 2721-27 1998) with the help of the NLS of the KON-21 accomplished.
  • the invention also includes methods for the treatment but also for the prevention of diseases.
  • the Kon21-DNA construct was produced using standard molecular biological techniques. For this, cDNA of the HeLa S3 cell line was amplified by means of PCR. The restriction sites for the subsequent cloning into a plasmid vector, as well as the sequence motifs necessary for the efficient translation of the mRNA, were introduced by using deoxyoligonucleotide primers which carried additional nucleotide sequences at their 5 'ends
  • the Kon21-DNA consuct was initially in the cloning vector pBluescript SK from Stratagene
  • Figure 1 shows the complete nucleotide sequence of the DNA insert and the encoded amino acid sequence of the expression product.
  • Figure 2 shows the structure of the Kon21 expression construct. Examples
  • the Kon21 protein is passed on to all cells in a culture.
  • CHO cells were transiently transfected with the construct pCEP4-Kon21 and analyzed at different times. For this purpose, the slides covered with cells were rinsed in PBS / 10% FCS, air-dried for about 6 hours and then fixed in chloroform / acetone. This was followed by immunofluorescence staining with the monoclonal antibody MIB-21, which specifically recognizes the KON-21 protein. The binding of the antibody MIB-21 was then detected using an Alexa488 conjugated goat anti-mouse antibody (Molecular Probes Inc., Eugene, Oregon, USA). For better orientation, the DNA of the cells was additionally counterstained with propidium iodide. To control the staining, CHO cells were also transfected with the expression vector pCEP4.
  • the KON-21 protein is taken up by all cells of a culture.
  • 500,000 CHO cells were transiently transfected with the construct pCEP4-Kon21. As a control, 500,000 CHO cells were also transfected with the expression vector pCEP4. After 24 hours incubation in the incubator, the cells were harvested, sedimented and the cell sediment was frozen at -70 ° C. After thawing, the cell sediment was resuspended in 500 ⁇ l ice-cold high-salt buffer (10 mM HEPES, pH 7.9, 400 mM NaCl, 0.1 M EDTA, 0.5 mM DTT, 5% glycerol) and after 5 minutes incubation at 0 ° C sedimented again.
  • 500 ⁇ l ice-cold high-salt buffer (10 mM HEPES, pH 7.9, 400 mM NaCl, 0.1 M EDTA, 0.5 mM DTT, 5% glycerol
  • the supernatant was added to CHO cells in 15 ml of culture medium and the cells were analyzed at different times.
  • the slides covered with the cells were rinsed in PBS / 10% FCS, air-dried for about 6 hours and then fixed in chloroform / acetone. ' This was followed by immunofluorescence staining with the monoclonal antibody MIB-21, which specifically recognizes the KON-21 protein.
  • the binding of the antibody MIB-21 was then detected using an Alexa488 conjugated Goat anti-mouse antibody (Molecular Probes Inc., Eugene, Oregon, USA).
  • the DNA of the cells was additionally counterstained with propidium iodide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation d'un fragment carboxy-terminal de la protéine Ki-67 ou d'une partie active, d'un fragment actif ou d'un homologue de ce dernier, en tant que composé approprié pour le transfert intracellulaire et l'absorption ou la sécrétion cellulaire. L'invention concerne en outre des composés de transfert qui contiennent l'extrémité carboxy-terminale, mentionnée ci-dessus, de la protéine Ki-67, ainsi que des vecteurs la codant. L'invention concerne en outre des compositions pharmaceutiques et l'utilisation de la protéine de transfert comme excipient ou principe actif dans le traitement de maladies.
EP00985060A 1999-11-18 2000-11-17 Composes de transfert, leur preparation et leur utilisation Withdrawn EP1234034A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19955576A DE19955576B4 (de) 1999-11-18 1999-11-18 Transferverbindungen, ihre Herstellung und ihre Verwendung
DE19955576 1999-11-18
PCT/EP2000/011482 WO2001036629A1 (fr) 1999-11-18 2000-11-17 Composes de transfert, leur preparation et leur utilisation

Publications (1)

Publication Number Publication Date
EP1234034A1 true EP1234034A1 (fr) 2002-08-28

Family

ID=7929531

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00985060A Withdrawn EP1234034A1 (fr) 1999-11-18 2000-11-17 Composes de transfert, leur preparation et leur utilisation

Country Status (8)

Country Link
US (1) US7189808B2 (fr)
EP (1) EP1234034A1 (fr)
JP (1) JP2003514529A (fr)
CN (1) CN1390257A (fr)
AU (1) AU773085B2 (fr)
CA (1) CA2391881A1 (fr)
DE (1) DE19955576B4 (fr)
WO (1) WO2001036629A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE365808T1 (de) * 1995-07-28 2007-07-15 Marie Curie Cancer Care Transportproteine und deren verwendungen
DE19822954A1 (de) * 1998-05-22 1999-11-25 Forschungszentrum Borstel Zent Antisense-Oligonukleotide zur Behandlung von proliferierenden Zellen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0136629A1 *

Also Published As

Publication number Publication date
JP2003514529A (ja) 2003-04-22
US7189808B2 (en) 2007-03-13
AU773085B2 (en) 2004-05-13
AU2160401A (en) 2001-05-30
US20030118600A1 (en) 2003-06-26
WO2001036629A1 (fr) 2001-05-25
CN1390257A (zh) 2003-01-08
DE19955576A1 (de) 2001-06-07
CA2391881A1 (fr) 2001-05-25
DE19955576B4 (de) 2008-02-28

Similar Documents

Publication Publication Date Title
DE69032284T2 (de) Expression von exogenen polynukleotidsequenzen in wirbeltieren
DE60207740T2 (de) Muteine von menschlichem mit neutrophiler Gelatinase-assoziiertem Lipocalin und damit verwandte Proteine
EP1427837B1 (fr) Systèmes de transfection modulaires à base de filaments de nucléoproteines
DE69329031T2 (de) Das dorsalgewebe beeinflussender faktor
DE69535063T2 (de) Denaturierter low-density lipoprotein (ldl) rezeptor
EP0973901B1 (fr) Flip-gene et flip-proteine
EP1349933A2 (fr) Proteines et sequences d'adn sous-jacentes a ces proteines, utilisees pour traiter les inflammations
EP4190802A1 (fr) Nouveau peptide de pénétration cellulaire et utilisation associée
DE60025480T2 (de) Methoden zur identifizierung von modulatoren wechselwirkender proteine
DE69725018T2 (de) Gereinigte telomerase
EP0805204B1 (fr) Protéine récepteur spécifique de l'épididyme et son utilisation
AT410672B (de) Nucleinsäure, die einen nervengewebe-natriumkanal kodiert
DE19955576B4 (de) Transferverbindungen, ihre Herstellung und ihre Verwendung
DE69025689T2 (de) Verfahren zur Herstellung von menschlicher Thiroid-Peroxydase
EP1436327B1 (fr) Famille de proteines ee3 et sequences d'adn correspondantes
WO2000017232A2 (fr) Proteine regulatrice issue de keratinocytes humains
WO2000040717A1 (fr) Methode de detection cellulaire a haut rendement d'interactions entre des recepteurs nucleaires et des ligands
DE602004003835T2 (de) Peptid-inhibitor der proteintranslation und dessen verwendung bei der steuerung der proteintranslation
DE4216321A1 (de) Untereinheiten von NMDA-Rezeptoren, Verfahren zu ihrer Herstellung und ihre Verwendung
EP1072681B9 (fr) Protéine regulatrice pKe#165 des kératinocytes humaines
EP1004668B1 (fr) Protéine régulatrice pKe 83 de keratinocytes humains
DE10064343A1 (de) Nukleinsäure für die Untersuchung des proteasomalen Proteinabbaus
DE19856301C1 (de) Regulatorisches Protein pKe#83 aus humanen Keratinozyten
WO1994010297A1 (fr) Procede de preparation de proteines gad-1 et gad-2 humaines de grande purete
Osborne Nuclear protein transport and nuclear structure in {\it Saccharomyces cerevisiae\/}

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020618

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20060622

17Q First examination report despatched

Effective date: 20060622

19U Interruption of proceedings before grant

Effective date: 20080320

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1049187

Country of ref document: HK

19W Proceedings resumed before grant after interruption of proceedings

Effective date: 20130301

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131204